Brief Communication | Published:

Recurrent mutations at codon 625 of the splicing factor SF3B1 in uveal melanoma

Nature Genetics volume 45, pages 133135 (2013) | Download Citation


Uveal melanoma is the most common primary cancer of the eye and often results in fatal metastasis. Here, we describe mutations occurring exclusively at codon 625 of the SF3B1 gene, encoding splicing factor 3B subunit 1, in low-grade uveal melanomas with good prognosis. Thus, uveal melanoma is among a small group of cancers associated with SF3B1 mutations, and these mutations denote a distinct molecular subset of uveal melanomas.

Access optionsAccess options

Rent or Buy article

Get time limited or full article access on ReadCube.


All prices are NET prices.


Primary accessions

Gene Expression Omnibus

Sequence Read Archive


  1. 1.

    Pigment Cell. Melanoma Res. 25, 171–181 (2012).

  2. 2.

    et al. Science 330, 1410–1413 (2010).

  3. 3.

    et al. Invest. Ophthalmol. Vis. Sci. 49, 5230–5234 (2008).

  4. 4.

    et al. Nature 457, 599–602 (2009).

  5. 5.

    et al. N. Engl. J. Med. 365, 1384–1395 (2011).

  6. 6.

    et al. N. Engl. J. Med. 365, 2497–2506 (2011).

  7. 7.

    et al. Nature 486, 353–360 (2012).

  8. 8.

    et al. N. Engl. J. Med. 363, 2191–2199 (2010).

  9. 9.

    , , , & Science 300, 980–984 (2003).

  10. 10.

    et al. Blood 120, 3173–3186 (2012).

  11. 11.

    & Int. J. Dev. Biol. 56, 223–237 (2012).

  12. 12.

    , , & Leukemia 26, 2447–2454 (2012).

  13. 13.

    , , , & Genes Dev. 19, 536–541 (2005).

Download references


This work was supported by US National Institutes of Health (NIH) grants R01 CA16187001 (A.M.B. and J.W.H.) and CA12597007 (J.W.H.), the Melanoma Research Alliance (J.W.H.), the Melanoma Research Foundation (J.W.H.), the Tumori Foundation (J.W.H.), Research to Prevent Blindness, Inc. (J.W.H.) and awards to the Department of Ophthalmology and Visual Sciences at Washington University from a Research to Prevent Blindness, Inc., Unrestricted grant and the US NIH Vision Core grant P30 EY02687c. E.D.O.R. was supported under US NIH training grant 5 T32 AR007279-32. We thank L. Cao for technical assistance and C. Jordan for exome capture. We thank the patients who volunteered to participate in the study in order to make this work possible. This study was approved by the Human Studies Committee at Washington University in St. Louis, and informed consent was obtained from all subjects.

Author information

Author notes

    • J William Harbour

    Present addresses: Bascom Palmer Eye Institute, University of Miami Miller School of Medicine, Miami, Florida, USA, and Sylvester Comprehensive Cancer Center, University of Miami Miller School of Medicine, Miami, Florida, USA.

    • J William Harbour
    •  & Anne M Bowcock

    These authors jointly directed this work.


  1. Department of Ophthalmology & Visual Sciences, Washington University School of Medicine, St. Louis, Missouri, USA.

    • J William Harbour
    • , Michael D Onken
    •  & Lori A Worley
  2. Department of Genetics, Washington University School of Medicine, St. Louis, Missouri, USA.

    • Elisha D O Roberson
    • , Hima Anbunathan
    •  & Anne M Bowcock


  1. Search for J William Harbour in:

  2. Search for Elisha D O Roberson in:

  3. Search for Hima Anbunathan in:

  4. Search for Michael D Onken in:

  5. Search for Lori A Worley in:

  6. Search for Anne M Bowcock in:


J.W.H. participated in the conception and design of the study, provided the samples used in the study, performed biostatistical analysis and drafted the manuscript. E.D.O.R. performed the analysis of next-generation sequencing data and bioinformatics analysis. H.A. performed Sanger sequencing. M.D.O. performed bioinformatics analysis. L.A.W. managed the tissue bank and clinical database and prepared DNA and RNA samples. A.M.B. participated in the conception and design of the study and analyzed the data. All authors contributed to the final draft of the manuscript.

Competing interests

J.W.H., A.M.B. and Washington University may receive income from the licensing of related technology by Washington University to Castle Biosciences, Inc. This work was not supported by Castle Biosciences, Inc.

Corresponding authors

Correspondence to J William Harbour or Anne M Bowcock.

Supplementary information

PDF files

  1. 1.

    Supplementary Text and Figures

    Supplementary Methods, Supplementary Tables 1 and 2 and Supplementary Figures 1–3

About this article

Publication history





Further reading